Bladder Neoplasm
25
5
6
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.0%
3 terminated out of 25 trials
66.7%
-19.8% vs benchmark
12%
3 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (25)
Virtuoso Improving Anatomic Bladder Lesion Excision Trial
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
Can VI-RADS/ADC Accurately Stage Bladder Cancer??
Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Comparison of Interfascial Injection Versus Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
Pre-Operative Single Shot Rectus Sheath Block
Personalized Urine Biomarker for Patients With Bladder Cancer
Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT
En-Bloc Resection of Bladder Tumors
Smurf2 Gene Expression in Urinary Tract Tumors
En Bloc TURBT With Collins Loop vs Conventional TURBT
Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block
Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder